Pharmaceutical Portfolio & Product Life Cycle Management


Published on

As product pipelines become thinner, and pressure to get the most out of dwindling resources increases, pharmaceutical portfolio and product lifecycle management becomes an imperative part of a company’s approach to maximizing ROI. Not only must managers carefully strategize in relation to the product’s strengths against competitors and also in such a way to compliment the overall company portfolio, but they must also balance the crucial factors of regulatory change in patent protection, risk mitigation, effective R&D resource allocation in order to achieve an integrated approach to effective portfolio and PLCM.

Now in its 6th year, SMi Groups Pharmaceutical Portfolio & Product Life-Cycle Management is a well established meeting ground for such managers and directors who are faced with the task of managing the pipeline in a way that acknowledges the above mentioned factors and more. In the close up environment that our conferences provide, you can expect to discuss with some of the leading professionals in the field the best way to approach this difficult task. In a showcase of effective approaches from many of the largest pharmaceutical companies, you can be sure to learn much of value to yourself, and to your organization.

Published in: Education
1 Like
  • Be the first to comment

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Pharmaceutical Portfolio & Product Life Cycle Management

  1. 1. REGISTER BY 28th FEBRUARY AND RECEIVE A £300 DISCOUNT REGISTER BY 31ST MARCH AND RECEIVE A £100 DISCOUNT SMi present their 6th annual conference on... Pharmaceutical Portfolio & Product Life-Cycle Management Wednesday 29th – Thursday 30th June 2011 Holiday Inn Bloomsbury, London KEY SPEAKERS INCLUDE Ulrich Betz Director, Department Head Centre of Innovation, Merck Serono Tony Ellery President, Ellery Pharma Consulting, Former Global Head LCM in Portfolio Management Novartis Alessio Merlin Director Strategic Planning Bayer Tim Harris Director Respiratory & Immuno-inflammation Portfolio Management GSK Getting the most out of your product Marie Bernasconi Global Program Team Director portfolio becomes paramount as Novartis budgets become more restricted. This Carmel Egan Vice President, Project Management conference provides a unique chance to Eli Lilly utilise the experiences of top level AT THIS CONFERENCE YOU WILL managers in developing successful • Discuss other’s approaches to fully integrated portfolio and PLCM management portfolio and product life-cycle • Learn of the latest EU patent regulatory guidance • Analyse the most effective risk mitigation strategies management strategies. • Debate the merits and drawbacks of portfolio out licensing • Network with our expert speaker line up PLUS A HALF-DAY POST-CONFERENCE WORKSHOP Tuesday 28th June 2011, Holiday Inn Bloomsbury, London Tools and Techniques for Optimal Drug Development Portfolio Planning: Portfolio Selection, Resource Allocation, and Risk Mitigation Workshop Leader: Vladimir Shnaydman, President, ORBee Consulting 1.30pm-5.30pmwww.pharma-portfolio.comRegister online and receive full information on all of SMi’s conferencesAlternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
  2. 2. Pharmaceutical Portfolio & ProductLife-Cycle ManagementDay One | Wednesday 29th June 2011 www.pharma-8.30 Registration and coffee 2.10 Where is the strategy in the strategy? • What does portfolio strategy mean in early phase?9.00 Chairmans opening remarks • Aligning Discovery, Clinical, Market Access and Commercial Tony Ellery, President, Ellery Pharma Consulting, Former Global • Integrating Value Proposition in early phase development: Head LCM in Portfolio Management, Novartis biomarkers, PROs, PE assessment9.10 Linking portfolio management with business strategy Mike Rea, Chief Executive Officer, IDEA Pharma • Developing an integrated approach to portfolio management • Closing the gap between theory and practise 2. 50 Holistic portfolio management at Bayer Schering Pharma • Adapting to the organisational culture • Key elements of portfolio management approach • Tips for successful integration Hans Hoogkamer, Business and Science Affairs, Actelion • Decision analysis process at R&D milestones Pharmaceuticals • Bridging strategy claims and operational reality Alessio Merlin, Director Strategic Planning, Bayer9.50 Integrated portfolio modelling (early to late) in support of strategy • Overview of the models, processes and outputs 3.30 Afternoon Tea • Different models for different insights • Gaining credibility: linking models with strategy • Learnings and challenges 3.50 Portfolio Management – It’s not about the numbers Michael OGrady, Portfolio-Analysis Manager, GlaxoSmithKline • Why Portfolio Management should not just focus on probabilities and NPVs10.30 Morning Coffee • How to integrate the context into the thinking • The fully integrated strategic portfolio10.50 Portfolio management: Integrated approaches to R&D • Aligning portfolio & productivity with corporate strategy Tim Harris Director, Respiratory & Immuno-inflammation Portfolio • How to identify, select and manage a new project from R&D and Management, GSK drive up performance • Informed and effective resource allocation 4.30 Managing a mixed portfolio: Making key decisions at the science, Mellor Hennessy, Global Portfolio Strategist, AstraZeneca* project, resource, and governance level • Managing diverse portfolios comprised of small chemical11.30 Tailoring R&D portfolio management to the needs of your company • The ‘must-haves’ and the ‘optionals’ in R&D portfolio management structures and a range of complex biomolecules • Requirements in companies of different sizes • Providing portfolio governance from discovery through • Managing the portfolio across the discovery/development interface commercialization, decision making and prioritization • Effective portfolio risk management • The factors involved in the reliable delivery of a blended portfolio Kerstin Bode-Greuel, Lecturer, University of Essen/PME Institute comprised of 30%-40% biomolecules12.10 Networking lunch • Lilly’s approach to achieve improved patient outcomes • Fully utilising the external universe of talent and capabilities to1.30 Project and portfolio risk analysis optimally manage a complex portfolio • Measuring Project and Portfolio Risk Carmel Egan, Vice President Project Management, Eli Lilly • Portfolio simulations. Monte Carlo analysis • Correlated risks in development portfolios 5.10 Chairmans Closing Remarks and Close of Day One • Risk mitigation Kimber Hardy, Head of Valuation and Analysis, Portfolio Management, Tony Ellery, President, Ellery Pharma Consulting, Former Global Merck Serono Head LCM in Portfolio Management, Novartis *Subject to confirmation Register online at • Alternatively faxWho should attend: Past attendee breakdown:Heads, Directors, Senior Directors, Managers, Vice Presidents andLeaders in the following areas: UK• Portfolio Management • Lifecycle Management• Portfolio Development • Product Strategy USA• Portfolio Coordinator • Product development Europe• Business Development • Programme management Other• Project management • Strategic Marketing• Valuation and Analysis • Brand development• Strategic Marketing • Generics Supported by
  3. 3. Pharmaceutical Portfolio & Product Life-Cycle Day Two | Thursday 30th June 2011 8.30 Re-registration and coffee 12.10 Networking lunch 9.00 Chairmans opening remarks 1.30 Life-cycle Management - Applied case study Tony Ellery, President, Ellery Pharma Consulting, Former Global Head • Early stage LCM: How to maximize value of products across lifecycle, LCM in Portfolio Management, Novartis when to implement and execute • Experiences of being close to the market 9.10 Partnerships, alliances and collaborations: Achieving successful • Lessons to be learned portfolio management Marie Bernasconi, Global Program Team Director, Novartis • Successful approaches • Case studies in collaborative portfolio development 2.10 Early stage strategies and intellectual property • Establishing then maintaining a mutually beneficial relationship • "Publish and be Damned!" (Duke of Wellington) - Patent issues in Arif Shivji, World Wide Business Development Director, Pfizer early stages • Patents as tools to assist portfolio management 9.50 PANEL DISCUSSION: • Patents as taskmasters in product lifecycles In-house portfolio vs. in-licensing/out-licensing strategies • Big Pharma R&D (Research & Development) vs. Big Pharma S&D • "Whats in a Name?" (Shakespeare) - Naming issues in early stages (Search & Development) • Trademarks considerations in product portfolios • Different approaches and experiences across pharmaceutical Julie Barret-Major, Director of Intellectual Property, Norgine industry • How the Biotech Company Strategies fit to these changes 2. 50 Afternoon Tea Sakir Mutevelic, Head of Global Project Management Biopharmaceuticals Hemophilia A / VWD, Baxter 3.30 EU Pharmaceutical Sector Inquiry and Antitrust Enforcement: Michael OGrady, Portfolio-Analysis Manager, GlaxoSmithKline • Main findings Arif Shivji, World Wide Business Development Senior Manager, Pfizer • Policy recommendations Marie Bernasconi, Global Program Team Director, Novartis • Antitrust enforcement Fabio Domanico, Case Handler, European Pharmaceuticals Sector Task 10.30 Morning Coffee Force, DG Competition – European Commission 10.50 New approaches towards managing a portfolio of innovation projects 4.10 An update on data protection developments : • Innovation management at Merck Serono • The global marketing authorization (MA) regarding various • Cross-divisional idea competition holders of MAs • Using new web2.0 tools • The global MA regarding racemate/enantiomer : • Fostering innovativeness and entrepreneurial thinking citalopram/escitalopram and zopiclone/eszopiclone cases Ulrich Betz, Director, Department Head Center of Innovation, Merck • What about the data protection of a new generation of a biologic Serono product ? 11.30 Creating and challenging LCM brand plans • The reference product • Selecting and implementing sustainable LCM strategies Elisabeth Berthet, Lawyer at the Paris Bar, Armengaud-Guerlain • Combining LCM strategies for maximum effectiveness • Credibility / robustness tests for LCM brand plans 4.40 Chairman’s Closing Remarks and Close of Day Two Tony Ellery, President, Ellery Pharma Consulting, Former Global Head Tony Ellery, President, Ellery Pharma Consulting, Former Global Head LCM in Portfolio Management, Novartis LCM in Portfolio Management, Novartisx your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711 ABOUT THE SMi PHARMACEUTICAL TEAM SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi have been involved in the pharmaceutical industry since 1993 and have SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. developed a series of informative and niche events, covering the latest Prime networking opportunities exist to entertain, enhance and expand issues and developments surrounding the industry. Events bring together your client base within the context of an independent discussion specific senior industry professionals and serving companies who have a focus on to your industry. Should you wish to join the increasing number of being at the forefront of developments in this area. SMi aim to generate companies benefiting from sponsoring our conferences please call: Alia informed and topical discussion through the medium of both conferences Malick on +44 (0) 20 7827 6168 or email: and executive briefings. Our pharmaceutical events are research-based and Want to know how you can get involved? content driven with regular contact with major industry personnel and cover Interested in promoting your pharmaceutical services to this market? a wide range of industry sectors. For more information, please visit Contact Jennifer Ireland, SMi Marketing on +44 (0)20 7827 6132, or email:
  4. 4. HALF DAY PRE-CONFERENCE WORKSHOP Tuesday 28th June 2011 1.30pm-5.30pm Holiday Inn Bloomsbury, London Tools and Techniques for Optimal DrugDevelopment Portfolio Planning: Portfolio Selection, Resource Allocation, and Risk Mitigation In association withOverview of WorkshopPortfolio planning is crucial for developing long-termcompany strategy. The goal is to select the “best” portfolioof internal and external drug development programs forfunding and to align company strategy with availableresources such as money, manpower and manufacturingcapacity, in order to mitigate portfolio risk. Buildingstrategic risk scenarios into portfolio planning can bufferthe organization against the unexpected. Examples mightbe clinical trial failure, shifts in the marketplace orinsufficient resource capacity. How to build in strategic riskinto long-term portfolio planning? How to align portfoliovalue, resources and risk? How to protect your profitsagainst unexpected events? How to simulate and analyzevariety of risk mitigation strategies? This workshop coversvarious portfolio planning tools and techniques with afocus on strategic risk management.1.30 Registration2.00 Welcome & Introductions2.10 Optimization of strategic portfolio planning • Technique overview • Components of portfolio optimization tool - Projects value – qualitative, quantitative (rNPV) - Resources – money, manpower - Business rules and strategic goals • Portfolio scenarios - Modification of strategic goals - Bottleneck analysis - Contingency planning2.45 Risk and uncertainty in portfolio planning • Strategic and operational risk • Risk assessment techniques • Flaw of averages3.45 Afternoon Tea4.00 Portfolio simulation for risk assessment and analysis of risk mitigation strategies • Workflow modelling • Portfolio simulation/animation • Portfolio value vs. risk • Analysis of risk mitigation strategies - Contingency planning - Growth options/secondary indications - Reformulation (new tricks for old drugs) - In- out-licensing5.00 Discussion Session5.30 Close of WorkshopAbout the workshop host Vladimir Shnaydman, Ph.D, is President of ORBee Consulting. Worked for Biogen Idec for several years, managing Biogen portfolio. Vladimir has BS & MS Electrical Engineering & Computer Science, MS in Applied Mathematics & Operations Research, and Ph.D. inEngineering. He contributed to many industries such asbiotechnology, computer networking, data storages, waterresources planning and management,telecommunications, transportation, and others. Dr.Shnaydman published more than 50 papers. He is co-author of three books.
  5. 5. PHARMACEUTICALFORWARD PLANNERFebruary 201102/03 Adaptive Designs in Clinical Drug Development07/08 Parallel Trade21/22 Advances and Progress in Drug Design23/24 Stem CellsMarch 201107/08 Imaging in Cancer Drug Development14/15 Pharmacovigilance16/17 Superbugs & Superdrugs23/24 Accelerating patient recruitment & Retention in Clinical Trials30/31 Controlled ReleaseApril 201113/14 Asthma & COPDMay 201111/12 Generics, Supergenerics and Patent Strategies16/17 Clinical Trial LogisticsJune 201101/02 Pain Therapeutics27/28 RNAi29/30 Nanotechnology29/30 Pharmaceutical Portfolio & Product Lifecycle Management29/30 KOL Europe (Munich, Germany)July 201106/07 ADMET11/12 BioBanking11/12 Social Media in the Pharmaceutical Industry18/19 Clinical Trial Logistics Asia (Singapore)20/21 Pre-Filled Syringes Asia (Singapore)All conferences take place in central London, UK– unless indicated otherwise in brackets ABOUT THE SMi PHARMACEUTICAL TEAM SMi have been involved in the pharmaceutical industry since 1993 and have developed a series of informative and niche events, covering the latest issues and developments surrounding the industry. Events bring together senior industry professionals and serving companies who have a focus on being at the forefront of developments in this area. SMi aim to generate informed and topical discussion through the medium of both conferences and executive briefings. Our pharmaceutical events are research-based and content driven with regular contact with major industry personnel and cover a wide range of industry sectors. For more information, please visit www.smi-
  6. 6. PHARMACEUTICAL PORTFOLIO & PRODUCT LIFE-CYCLE MANAGEMENT Conference: Wednesday 29th – Thursday 30th June 2011, Holiday Inn Bloomsbury, London, UK Workshop: Tuesday 28th June 2011, London 4 WAYS TO REGISTER www.pharma-portfolio.comFAX your booking form to +44 (0) 870 9090 712 POST your booking form to: Events Team, SMi Group Ltd, Great GuildfordPHONE on +44 (0) 870 9090 711 Business Square, 30 Great Guildford Street London, SE1 0HS, UK EARLY BIRD □ Register by 28th February and Receive a £300 Discount DISCOUNT □ Register by 31st March and Receive a £100 Discount CONFERENCE PRICES I would like to attend: (Please tick as appropriate) Fee Total □ Conference & Half-Day Workshop £1998.00 +VAT £2397.60 □ Conference only £1399.00 + VAT £1678.80Unique Reference Number □ Half-Day Workshop £599.00 + VAT £718.80Our Reference LVY19 PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotionalDELEGATE DETAILS literature to all conference attendees £999.00 + VAT £1198.80Please complete fully and clearly in capital letters. Please photocopy for additional delegates.Title: Forename: GROUP DISCOUNTS AVAILABLESurname: The Conference fee includes refreshments, lunch, conference papers andJob Title: CD ROM containing all of the presentations.Department/Division:Company/Organisation:Email: VENUE Holiday Inn, London - Bloomsbury, Coram Street, London WC1N 1HT, London, UKAddress: □ Please contact me to book my hotel Alternatively call us on +44 (0) 870 9090 711, email: or fax +44 (0) 870 9090 712Town/City:Post/Zip Code: Country: CD ROMS/DOCUMENTATIONDirect Tel: Direct Fax: I cannot attend but would like to purchase the following CD ROMs:Mobile: (Shipped 10-14 days after the event) Price TotalSwitchboard: □ Conference presentations on CD ROM (Slides only) £499.00 +VAT £598.80 □ The conference presentations – paper copy £499.00 - £499.00Signature: Date:I agree to be bound by SMis Terms and Conditions of Booking.ACCOUNTS DEPT PAYMENTTitle: Forename: Payment must be made to SMi Group Ltd, and received before the event, by one of theSurname: following methods quoting reference Y19 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment are below. PleaseEmail: indicate method of payment:Address (if different from above): □ UK BACS Sort Code 300009, Account 00936418 □ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18Town/City: □ Cheque We can only accept Sterling cheques drawn on a UK bank.Post/Zip Code: Country: □ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.Direct Tel: Direct Fax: Card No: □□□□ □□□□ □□□□ □□□□Terms and Conditions of Booking Valid From □□/□□ Expiry Date □□/□□ CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX cardPayment: If payment is not made at the time of booking, then an invoice will be issued and must bepaid immediately and prior to the start of the event. If payment has not been received then credit carddetails will be requested and payment taken before entry to the event. Bookings within 7 days ofevent require payment on booking. CD Roms will not be dispatched until payment has been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another Cardholder’s Name:delegate to take your place at any time prior to the start of the event. Two or more delegates maynot ‘share’ a place at an event. Please make separate bookings for each delegate. Signature: Date:Cancellation: If you wish to cancel your attendance at an event and you are unable to send a I agree to be bound by SMis Terms and Conditions of Booking.substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,providing that cancellation is made in writing and received at least 28 days prior to the start of theevent. Regretfully cancellation after this time cannot be accepted. We will however provide the Card Billing Address (If different from above):Conference documentation on CD ROM to any delegate who has paid but is unable to attend for anyreason. Due to the interactive nature of the Briefings we are not normally able to providedocumentation in these circumstances. We cannot accept cancellations of orders placed forDocumentation or CD ROM as these are reproduced specifically to order. If we have to cancel theevent for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing,venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data ProtectionAct 1998 and we may use this to contact you by telephone, fax, post or email to tell you about otherproducts and services. Unless you tick here □ we may also share your data with third parties VAToffering complementary products or services. If you have any queries or want to update any of thedata that we hold then please contact our Database Manager VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on CDor visit our website quoting the URN as detailed above your ROMs and Literature Distribution for all UK customers and for those EU customers notaddress on the attached letter. supplying a registration number for their own country here: _______________________ If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at